Herb Research Foundation
"Improving world health and well being through herbs"

Saw Palmetto

(Seronoa repens)


All articles are $20. Click Review Order button below
to view what you have selected and make any adjustments

Review Order

Bach D, Ebeling L. Long-term drug treatment of benign prostatic hyperplasia-- results of a prospective 3-year multicenter study using Sabal extract IDS 89. Phytomedicine 1996; 3(2): 105-111.

Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of ß-sitosterol in patients with benign prostatic hyperplasia. The Lancet 1995; 345: 1529-1532.

Braeckman J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Current Therapeutic Research 1994; 55(7): 776-785.

Braeckman J, Bruhwyler J, Vandekerckhove K, et al. Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms. Phytotherapy Res 1997; II: 558-563.

Breu W, Hagenlocher M, Redl K, et al. Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide: in vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism [German]. Arzneim-Forschung/Drug Res 1992; 42(1): 547-551. (German paper with English summary)

Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. British Journal of Urology 1990; 66: 639-641.

Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. The Prostate 1996; 29: 231-240.

Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984; 18: 461-462.

Descotes JL, Rambeaud JJ, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995; 9(5): 291-297.

Gutiérrez M, Hidalgo A, Cantabrana B. Spasmolytic activity of a lipidic extract from Sabal serrulata fruits: further study of the mechanisms underlying this activity. Planta Medica 1996; 62: 507-511.

Kondas J, Philipp V, Dioszeghy G. Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia. International Urology and Nephrology 1996; 28(6): 767-72.

Rhodes L, Primka RL, Berman C, et al.Comparison of finasteride (Proscar®), a 5a reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5a reductase inhibition. The Prostate 1993; 22: 43-51.

Romics I, Schmitz H, Frang D. Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year. International Urology and Nephrology 1993; 25(6): 565-569.

Strauch G, Perles P, Vergult G, et al. Comparison of finasteride (Proscar®) and Serenoa repens (Permixon®) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994; 26: 247-252.